In ovarian cancer models, an oncolytic vaccinia virus engineered to deliver a CXCR4 antagonist designed as a mouse Fc fragment of IgG2a inhibited tumor growth by reducing recruitment of regulatory T-cells with concomitant increased antitumor immune responses and destruction of tumor-initiating cells [31]. This evidence concerns the gene CXCR4 and ovarian carcinoma.